Plain-English translation of NCT07126678 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a combination of three medications——given together to treat advanced follicular lymphoma in patients who have never been treated for lymphoma before. You would receive this medication combination over six months (six cycles of treatment), then stop—there is no long-term maintenance therapy. The goal is to see how well this fixed-duration approach works and how safe it is.
Follicular lymphoma is a slow-growing blood cancer that often comes back after treatment. Researchers want to find out if this particular three-drug combination, given for a set period and then stopped, can help patients achieve long-lasting remission without needing ongoing therapy.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital or clinic regularly over six months to receive treatment. Two of the medications (bendamustine and obinutuzumab) are given by IV infusion on specific days during each four-week cycle, while the third medication (zanubrutinib) is a pill you take by mouth twice daily throughout the six months. After completing the six cycles, your treatment stops—you won't need ongoing maintenance therapy. The study team will monitor how well the treatment works and watch for any side effects through blood tests and imaging scans.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China